Abby Hardy, Author at BioTuesdays

Markets

Alliance Global starts T2 Biosystems at buy; PT $5.00

Alliance Global Partners launched coverage of T2 Biosystems (NASDAQ:TTOO) with a “buy” rating and price target of $5.00. The stock closed at $2.62 on May 15.

May 16, 2019

Developments

Principia Biopharma doses first patient in Phase 2b MS trial

Principia Biopharma (NASDAQ:PRNB) has dosed the first patient in its Phase 2b clinical trial of SAR442168 in patients with relapsing multiple sclerosis (MS). Neuroinflammation and an increase in the number of B cells in...

May 15, 2019

Developments

Athersys gets FDA fast track designation for acute respiratory distress syndrome

Athersys’ (NASDAQ:ATHX) MultiStem cell therapy for the treatment of acute respiratory distress syndrome (ARDS) has received FDA fast track designation. ARDS is a widespread inflammation of the lungs that can be...

May 15, 2019

Markets

Roth starts Seelos Therapeutics at buy; PT $8

Roth Capital partners launched coverage of Seelos Therapeutics (NASDAQ:SEEL) with a “buy” rating and $8 price target. The stock closed at $2.71 on May 13.

May 14, 2019

Markets

Alliance Global starts Canopy Growth at buy; PT $75 (Canadian)

Alliance Global Partners launched coverage of Canopy Growth (TSX:WEED; NYSE:CGC) with a “buy” rating and $75 price target. The stock closed at $63.78 on May 10.

May 13, 2019

Developments

Titan Pharma in pact with Express Scripts’ Accredo to further expand patient access to Probuphine

Titan Pharmaceuticals (NASDAQ:TTNP) signed a product purchase and supply agreement with Accredo specialty pharmacy, a subsidiary of Express Scripts, further expanding patient access to its Probuphine implant for the...

May 13, 2019

Developments

Magenta Therapeutics reports initial Phase 2 data for stem cell therapy

Magenta Therapeutics (NASDAQ:MGTA) reported preliminary data from its Phase 2 trial testing MGTA-456, a hematopoietic stem cell (HSC) therapy, in patients with inherited metabolic disorders. The Phase 2 study is...

May 10, 2019

Developments

Genetic Technologies validates two cancer risk assessment tests

Genetic Technologies (ASX:GTC; NASDAQ:GENE) has validated risk assessment tests for colorectal cancer in individuals with no known pathogenic gene variant, and for breast cancer in individuals who do not have a family...

May 10, 2019

Developments

Alder BioPharma reports new Phase 3 data for eptinezumab for migraines

Alder BioPharma (NASDAQ:ALDR) reported new data from its Phase 3 trial of eptinezumab, a monoclonal antibody targeting the calcitonin gene-related peptide (CGRP), for the prevention of migraines. Nearly 60% of patients...

May 9, 2019

Developments

Zynerba Pharma Zygel gets FDA fast track designation for Fragile X

The FDA granted Zynerba Pharma’s (NASDAQ:ZYNE) Zygel fast track designation for behavioral symptoms associated with Fragile X syndrome. Fragile X syndrome, a rare genetic condition caused by a mutation in the X...

May 6, 2019

Author - Abby Hardy

Alliance Global starts T2 Biosystems at buy; PT $5.00

Principia Biopharma doses first patient in Phase 2b MS trial

Athersys gets FDA fast track designation for acute respiratory distress syndrome

Roth starts Seelos Therapeutics at buy; PT $8

Alliance Global starts Canopy Growth at buy; PT $75 (Canadian)

Titan Pharma in pact with Express Scripts’ Accredo to further expand patient access to Probuphine

Magenta Therapeutics reports initial Phase 2 data for stem cell therapy

Genetic Technologies validates two cancer risk assessment tests

Alder BioPharma reports new Phase 3 data for eptinezumab for migraines

Zynerba Pharma Zygel gets FDA fast track designation for Fragile X

Subscribe